Semaglutide with Basal Insulin Effective in Diabetes Management: Study
A new systematic review and meta-analysis published in the Clinical Nutrition ESPEN revealed promising outcomes for the combined use of semaglutide and basal insulin in managing type 2 diabetes mellitus (T2DM). This study analyzed 7 randomized controlled trials (RCTs) which involved 2,354 patients and found significant improvements in glycemic control and weight loss without a higher risk of serious adverse events.
The primary measure of the research was to assess changes in hemoglobin A1c (HbA1c) levels. Secondary outcomes included weight loss, fasting blood glucose (FPG) changes, and the incidence of adverse effects, including gastrointestinal reactions.
The patients who received a combination of semaglutide and basal insulin experienced a substantial reduction in HbA1c levels, with a mean difference of -1.17% when compared to placebo or other treatments. Weight loss was also notable, where the patients shed an average of 5.99 kg, and fasting blood glucose levels dropped by 1.08%.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.